Corrigan Minehan Heart Center and Division of Cardiac Surgery, Massachusetts General Hospital, Boston, Mass; Department of Surgery, Massachusetts General Hospital, Boston, Mass.
Department of Surgery, Massachusetts General Hospital, Boston, Mass.
J Thorac Cardiovasc Surg. 2022 Oct;164(4):1222-1233.e11. doi: 10.1016/j.jtcvs.2021.11.086. Epub 2021 Dec 13.
Approximately 40% of lung transplants for chronic obstructive pulmonary disease (COPD) in the lung allocation score era are single lung transplantations (SLTs). We hypothesized that double lung transplantation (DLT) results in superior survival, but that mortality on the waitlist may compel clinicians to perform SLT. We investigated both waitlist mortality in COPD patients with restricted versus unrestricted listing preferences and posttransplant survival in SLT versus DLT to identify key predictors of mortality.
A retrospective analysis of waitlist mortality and posttransplant survival in patients with COPD was conducted using post-lung allocation score data from the United Network for Organ Sharing database between 2005 and 2018.
Of 6740 patients with COPD on the waitlist, 328 (4.87%) died and 320 (4.75%) were removed due to clinical deterioration. Median survival on the waitlist was significantly worse in patients listed as restricted for DLT (4.39 vs 6.09 years; P = .002) compared with patients listed as unrestricted (hazard ratio, 1.34; 95% CI, 1.13-1.57). Factors that increase waitlist mortality include female sex, increased pulmonary artery pressure, and increased wait time. Median posttransplant survival was 5.3 years in SLT versus 6.5 years in DLT (P < .001). DLT recipients are younger, male patients with a higher lung allocation score. The survival advantage of DLT persisted in adjusted analysis (hazard ratio, 0.819; 95% CI, 0.741-0.905).
Restricted listing preference is associated with increased waitlist mortality, but DLT recipients have superior posttransplant survival. Because the lung allocation score does not prioritize COPD, concern for increased waitlist mortality with restricted listing preference may drive continued use of SLT despite better posttransplant survival in DLT.
在肺分配评分时代,大约 40%的慢性阻塞性肺疾病(COPD)肺移植为单肺移植(SLT)。我们假设双肺移植(DLT)可带来更好的生存结果,但在等待名单上的死亡率可能迫使临床医生进行 SLT。我们研究了 COPD 患者在受限和不受限的名单偏好下的等待名单死亡率,以及 SLT 与 DLT 后的移植后生存情况,以确定死亡率的关键预测因素。
使用 2005 年至 2018 年美国器官共享网络数据库中的肺分配评分后数据,对 COPD 患者的等待名单死亡率和移植后生存情况进行回顾性分析。
在等待名单上的 6740 名 COPD 患者中,328 人(4.87%)死亡,320 人(4.75%)因临床恶化而被移除。与不受限制的 DLT 名单(中位生存时间为 4.39 年)相比,受限的 DLT 名单(中位生存时间为 6.09 年;P=.002)的患者等待名单上的中位生存时间明显更差(危险比,1.34;95%CI,1.13-1.57)。增加等待名单死亡率的因素包括女性、肺动脉压升高和等待时间延长。SLT 的中位移植后生存时间为 5.3 年,而 DLT 的中位生存时间为 6.5 年(P<.001)。DLT 受者为年龄较小、男性、肺分配评分较高的患者。在调整后的分析中,DLT 的生存优势仍然存在(危险比,0.819;95%CI,0.741-0.905)。
受限的名单偏好与增加的等待名单死亡率相关,但 DLT 受者的移植后生存更好。由于肺分配评分没有优先考虑 COPD,对受限的名单偏好增加的等待名单死亡率的担忧可能会继续推动 SLT 的使用,尽管 DLT 的移植后生存更好。